Introduction {#s0010}
============

Prior to the Human Genome Project, it was estimated that human genomes contained roughly 100,000 genes encoding proteins ([@bib372]). In actuality, humans possess only ∼20,000 protein-coding genes, which is 10,000 more than the fruit fly, *Drosophila melanogaster*, and 15,000 fewer than rice, negating the hypothesis that the number of genes correlated with complexity of the organism ([@bib276]). It is now apparent that only 2% of the human genome codes for proteins, whereas the remaining 98% is composed of endogenous retroviruses (ERVs) and noncoding RNA (ncRNA) ([@bib118]). Although a limited percentage of the genome produces proteins, approximately 90% is transcribed, indicating important roles for ncRNA ([@bib397], [@bib31], [@bib103]). The term "ncRNA" applies to any RNA that is not translated into protein ([@bib275]). Generally, ncRNAs are divided into groups based on their size and activity, although other classification systems are sometimes used ([@bib275], [@bib124], [@bib363]). Ribosomal RNA (rRNA) and transfer RNA (tRNA) are the most well-characterized species of ncRNA, which are both integral components of mRNA translation ([@bib275]). The untranslated regions (UTRs) of mRNAs can also be classified as ncRNA, and play critical roles in the regulation of mRNA translation, as well as viral life cycles ([@bib275]). Small ncRNAs (generally \<200 nt) include small nuclear RNA (snRNA), microRNA (miRNA), tRNA-derived fragments (tRFs), piwi-interacting RNA (piRNA), repeat-associated small interfering RNA, and Y RNAs ([@bib397], [@bib275], [@bib26]). Long ncRNAs (lncRNAs) are longer than 200 nts, more loosely classified, and less well understood ([@bib124], [@bib280], [@bib325]). For more in-depth analysis of small ncRNA and lncRNA nomenclature and functions see reviews by [@bib275] and [@bib363].

Because viral genomes are compact, the evolutionary conservation of proteins and ncRNA underscores their importance in the viral life cycle ([@bib388]). The first viral ncRNAs were identified in 1966 and were isolated from the adenovirus ([@bib319]). These RNAs were found to counteract protein kinase R (PKR) through competitive binding with viral dsRNA transcripts, blocking the host's ability to sense infection ([@bib88]). ncRNAs have been found to have functions at nearly every step of viral replication cycles ([@bib81]). For example, many viruses use internal ribosomal entry sites (IRESs) to preferentially translate viral mRNA over host mRNA ([@bib304], [@bib181]). Some retroviruses and all coronaviruses exploit RNA structures to cause ribosomal frameshifting resulting in the Gag-Pol and 1a/1b polyproteins, respectively ([@bib45]). Specific RNA structures within viral RNA can also enhance transcription and exportation of viral RNA from the nucleus ([@bib112], [@bib192], [@bib111], [@bib267]). RNA interference (RNAi), thought to be an early version of the innate immune response to viral infection, can still be observed in plants and invertebrates today, as discussed in more detail later in this chapter ([@bib81], [@bib399]). Many viruses produce miRNAs to counteract host responses and defenses ([@bib388]), and retroviruses and long terminal repeat (LTR) retrotransposons use host tRNAs to prime reverse transcription ([@bib416], [@bib264]). This chapter will focus on ncRNAs of both host and viral origin and their roles in retroviral replication cycles.

Host RNAs Packaged Into Virions {#s0015}
===============================

It is estimated that RNA constitutes approximately 50% of the mass of retroviral particles; roughly half of retroviral RNA by weight is cellular RNA ([@bib40], [@bib28], [@bib39], [@bib101]). The most commonly found RNAs packaged into retrovirus virions, excluding viral RNA and tRNAs, are host mRNA, 7SL RNA, U snRNA, Y RNA, and vault RNA (typically abbreviated vtRNA or vRNA, but here it is represented by vltRNA to avoid confusion with viral tRNAs and viral RNA), a majority of which are ncRNA ([@bib40], [@bib378], [@bib296], [@bib297], [@bib99], [@bib32], [@bib126], [@bib121], [@bib8]). Host mRNAs are a minority species of RNA packaged into retrovirus virions ([@bib297], [@bib152], [@bib286]). Generally, the amount of packaged mRNA is proportional to the concentration within the host cell in the absence of viral genomic RNA ([@bib208]). In addition, mRNAs packaged in place of genomic RNA tend to have longer 3′ UTRs, a common feature of retroviral genomic RNA, suggesting the length of the 3′UTRs may be a determinant for packaging ([@bib208], [@bib273]). Initially, it was hypothesized that packaging of cellular RNAs was either random or a contamination of the purified virions, and that these RNAs did not play a significant role in the retrovirus life cycle ([@bib40], [@bib425], [@bib150]). However, as more roles for ncRNA in the cell began to emerge it became clear that these RNAs may indeed participate in the viral life cycle. Below, the most common RNAs packaged into virions will be described and potential packaging mechanisms will be briefly discussed.

Transfer RNAs {#s0020}
-------------

During reverse transcription, retroviruses, retrotransposons, and plant viruses known as pararetroviruses, which replicate through an RNA intermediate and are also reverse transcribed, use host tRNAs as primers for cDNA synthesis ([@bib264], [@bib139], [@bib279], [@bib154], [@bib272]). Each virus contains a primer-binding site (PBS) in their 5′ UTR that is complementary to 8--18 nucleotides (nt) of a host tRNA ([@bib264], [@bib272]) ([Table 12.1](#t0010){ref-type="table"} ). Generally, the 3′ acceptor stem of the tRNA is unwound and annealed to the PBS ([@bib272]). However, for some members of the retrotransposon Ty1/copia and Ty5 groups, priming begins at an internal site of the tRNA overlapping the anticodon stem loop ([@bib400]). Interestingly, T1 retrotransposons found in *D. melanogaster* were directly shown to be primed by a fragment of ${\text{tRNA}_{\text{i}}}^{\text{Met}}$ instead of the full-length tRNA that is thought to be the primer in most other cases ([@bib272], [@bib400], [@bib336]). It has been suggested that a fragment of tRNA^Pro^ (tRF-3019) could also be substituted for the primer tRNA in human T-cell leukemia virus (HTLV) ([@bib332], [@bib349]). tRF-3019 produced from the 3′ acceptor stem was found to prime RT in vitro and was detected in viral particles collected from HTLV-infected cells ([@bib332]).Table 12.1Proposed Host Transfer RNAs (tRNAs) Used as Primers for Retroviral Reverse TranscriptionGeneraVirusHost SpeciesPrimerReferences*Alpharetrovirus*ALV/RSVAviantRNA^Trp^[@bib342]*Betaretrovirus*MMTVMurinetRNA^Lys3^[a](#tbl14_1fna){ref-type="table-fn"}[@bib263]Mason--Pfizer monkey virusMacacatRNA^Lys1,2^[@bib231]*Gammaretrovirus*MLVMurinetRNA^Pro,\ Glu^[@bib376] and [@bib74]GALVPrimatetRNA^Pro^[@bib90]FLVFelinetRNA^Pro^[@bib222]*Deltaretrovirus*BLVBovinetRNA^Pro^[@bib76]HTLV*H. sapiens*tRNA^Pro^[@bib350]*Epsilonretrovirus*Walleye dermal sarcoma*Sander vitreus*tRNA^His^[@bib160]*Lentivirus*HIV-1, HIV-2*H. sapiens*tRNA^Lys3^[@bib402]SIVPrimatetRNA^Lys3^[@bib27]EIAVEquinetRNA^Lys3^[@bib195]FIVFelinetRNA^Lys3^[@bib281]*Spumavirus*SFVPrimatetRNA^Lys1,2^[@bib317] and [@bib343]PFVPrimatetRNA^Lys1^[@bib277]EFVEquinetRNA^Lys1^[@bib381]FFVFelinetRNA^Lys1^[@bib324]BFVBovinetRNA^Lys1^[@bib268]*Endogenous*CHIA34Chinese HamstertRNA^Phe^[@bib242]PERVPorcinetRNA^Gly,\ Pro^[@bib6] and [@bib21]Squirrel MonkeySaimirinaetRNA^Lys1,2^[@bib67]Jaagsiekte sheep*Ovis aries*tRNA^Lys1,2^[@bib51]HERV*H. sapiens*tRNA^Lys^[b](#tbl14_1fnb){ref-type="table-fn"}[@bib384]AKVAKR micetRNA^Glu^[@bib291]KoRVPhascolarctostRNA^Pro^[@bib149]MINERVaMiniopteridaetRNA~Pro~[@bib109]*Rhinolophus ferrumequinum* retrovirus (RfRV)*R. ferrumequinum*tRNA^Pro^[@bib80]*Retrotransposons*Ty1, Ty2*Saccharomyces cerevisiae*${\text{tRNA}_{\text{i}}}^{\text{Met}}$[@bib117]tom*Drosophila*tRNA^Ser^[@bib365]Ty4*S. cerevisiae*tRNA^Asn^[@bib400]Ty5*S. cerevisiae*${\text{tRNA}_{\text{i}}}^{\text{Met}}$-fragment[@bib400]Copia*Drosophila*${\text{tRNA}_{\text{i}}}^{\text{Met}}$-fragment[@bib204]Gypsy*Drosophila*tRNA^Lys^[@bib336] and [@bib362]mdg1 and 412*Drosophila*tRNA^Arg^[@bib386]Elements 297 and 17.6*Drosophila*tRNA^Ser^[@bib272]mdg.3*Drosophila*tRNA^Leu^[@bib272]Ty3*S. cerevisiae*${\text{tRNA}_{\text{i}}}^{\text{Met}}$[@bib311][^1][^2][^3]

Low levels of tRFs are present under homeostatic conditions, however specific cleavage of tRNAs occurs under stress conditions (oxidative stress, heat shock, UV radiation, and viral infection) ([@bib11], [@bib360]). The biological function of at least some tRFs is thought to involve the RNA silencing pathway, and exogenous expression of the 5′ acceptor stem fragments results in a 10%--15% reduction in global translation ([@bib11], [@bib105]). Production of tRFs is also found in human cancers and may play a role in neurodegenerative diseases ([@bib11]). Recently, two tRFs were characterized across several mouse stem cell lines ([@bib347]). tRFs (18 -nt) derived from the 3′ terminus of tRNA^Lys3^ were found to interfere with reverse transcription of ERVs, maintaining viral expression but limiting the mobility of the retroelements ([@bib347]). Additionally, 22-nt tRFs also derived from the 3′ end of tRNA^Lys3^ resulted in posttranscriptional silencing of viral RNA and proteins ([@bib347]). These tRFs allow for fine tuning of ERV expression, many of which are thought to have gained regulatory roles in the host cells as described below.

tRNA maturation is highly regulated and involves processing 3′ and 5′ leader sequences, excision of introns, if present, and extensive nucleotide modification ([@bib309]). The process of tRNA maturation is further complicated by several nuclear export and import steps to proofread some tRNA species ([@bib161]). Intriguingly, some pre-tRNAs are packaged into MLV and HIV-1 virions, although the function of these RNAs is not known ([@bib99]). Limiting the expression of a transport protein known to export pre-tRNAs, exportin-5, blocked packaging of pre-tRNAs into MLV and HIV-1 virions ([@bib99]). This finding suggests that pre-tRNAs, and potentially other RNAs packaged into retroviral virions, are recruited shortly after transcription.

The evolutionary selection of one primer tRNA over another is not well understood ([@bib272]). In some cases, a subpopulation of cellular tRNAs is packaged into virions or virus-like particles (VLPs) at ratios that differ from the host pool, suggesting that these tRNA species are selectively packaged ([@bib416], [@bib272], [@bib200], [@bib265]). For example, tRNA^Trp^, the primer for avian leucosis virus (ALV), accounts for 32% of the tRNA packaged into virions, in contrast to 1.4% of the tRNA found in cells ([@bib416]). Additionally, human tRNA^Lys3^ serves as the primer in HIV-1, and tRNA^Lys^ isoacceptors represent approximately 50%--60% of the low-molecular weight RNA within the HIV-1 virion, but only 5%--6% within the cell ([@bib265]). A similar trend, albeit less striking, is observed for Moloney murine leukemia virus (MLV), where primer tRNA^Pro^ constitutes 5%--6% of cellular low-molecular weight RNA and 12%--24% of low-molecular weight vRNA ([@bib416]). Retrotransposons also package their primer tRNAs into VLPs; the relative concentration of tRNA~i~ ^Met^ increases 10- to 40-fold in Ty1 VLPs ([@bib400], [@bib313]).

The mechanism by which tRNA primer enrichment occurs is not known. However, in some instances the cognate aminoacyl-tRNA synthetase is also packaged ([@bib52], [@bib53]). In the case of HIV-1, human lysyl-tRNA synthetase (LysRS) is packaged into HIV-1 virions ([@bib52]). Knockdown of LysRS, which interacts with the CA domain of HIV-1 Gag, reduces the levels of tRNA^Lys^ packaged into virions, as well as viral infectivity, suggesting that primer tRNA^Lys3^ packaging is facilitated through LysRS ([@bib52], [@bib54], [@bib146], [@bib92], [@bib141], [@bib184]). Intriguingly, upstream of the PBS in the NL4-3 (subtype B) HIV-1 gRNA there is a stem loop that mimics both the secondary and tertiary structure of the anticodon stem loop of tRNA^Lys3^ and contains exposed uridine residues critical to LysRS binding ([@bib186], [@bib187], [@bib249]). Mutation of the uridine residues in the tRNA-like element (TLE) to adenines reduced LysRS binding, as well as primer placement of tRNA^Lys3^ on the PBS, inhibiting reverse transcription and viral infection ([@bib186]). This tRNA mimicry is also found in the MAL isolate (subtype A-like) of HIV-1, suggesting conservation of TLEs across distinct HIV subtypes ([@bib75]). Overall, HIV-1 Gag is proposed to bind tRNA^Lys^-bound LysRS and recruit the complex to sites of virion assembly where the TLE effectively competes for LysRS binding, causing the release of the primer and facilitating efficient annealing ([@bib186], [@bib214]).

Mutagenesis studies have been carried out to determine the importance of the specific PBS sequence in retroviral replication ([@bib421], [@bib86], [@bib256], [@bib323], [@bib404]). The PBS of HIV-1 is the best characterized of any retrovirus. Deletions of the entire PBS or nt 1--9 did not produce infectious virus ([@bib323]). However, deletion of nt 10--18, 7--18, or replacement of nt 7--18 with random nt resulted in delayed production of functionally active virus. Upon sequencing, these virions were found to contain an 18-nt region that was once again fully complementary to tRNA^Lys3^. Nucleotide insertions and deletions were found 3′ to the PBS suggesting that tRNA^Lys3^ did in fact anneal to the PBS resulting in the reversion to the wild-type (WT), tRNA^Lys3^ specific, PBS ([@bib323]). Multiple studies mutating the PBS region of HIV-1 to become complementary to different tRNAs produced infectious virions utilizing the substituted tRNA ([@bib86], [@bib403]). However, every virus reverted back to a PBS specific for tRNA^Lys3~,~^ indicating a selective advantage in the use of this particular tRNA. Interestingly, an HIV-1 virus with a PBS complementary to tRNA^His^ was maintained by mutating residues within the HIV-1 genome that are thought to further stabilize interactions with the tRNA outside of the 3′ 18 -nt, indicating that residues outside of the PBS may play a role in tRNA use ([@bib404], [@bib27]). Furthermore, packaging of tRNA^Lys^ occurs independently of HIV-1 genomic RNA packaging, which could contribute to the selective pressure in maintaining a WT PBS ([@bib169]).

Similarly to HIV-1, mutations to the PBS of ALV allowing for the use of tRNA^Pro^, tRNA^Lys^, tRNA^Met^, tRNA^Ile^, tRNA^Phe^, and tRNA^Ser^ resulted in short-term maintenance of the mutated PBS and delayed infection followed by reversion to the WT PBS-Trp, suggesting that although other tRNAs can be used, there is a distinct infectivity advantage for the WT PBS ([@bib421]). Interestingly, MLV appears to be more permissive to PBS mutations. Mutation of the PBS matching tRNA^Pro^ to sequences accommodating tRNA^Glu^ or tRNA^Lys^ produced infectious single-cycle replication-competent virus, suggesting that the PBS did not require perfect nt base pairing for efficient priming ([@bib256]). Additionally, using a randomized PBS it was found that MLV replicated efficiently with tRNA^Arg(CUC)^, tRNA^Phe(GAA)^, and tRNA^Ser(CGA)^ ([@bib257]); however, it is possible, based on studies with HIV-1 and ALV, that after a longer period, the sequence would revert back to WT, which was not tested.

Another function of host tRNAs in the retroviral lifecycle is Gag membrane targeting. Phosphatidylinositol (4,5) bisphosphate (PI(4,5)P~2~)is associated with the cytosolic inner leaflet of the plasma membrane (PM) and acts as a targeting mechanism for PM-localized proteins ([@bib397], [@bib31] [@bib393], [@bib298]). In some retroviruses, including HIV-1, the matrix (MA) domain of Gag binds to PI(4,5)P~2~, targeting Gag to the plasma membrane ([@bib298], [@bib294], [@bib177], [@bib178], [@bib68]). Plasma membrane targeting of HIV-1 Gag is mediated through a bipartite signal consisting of a myristic acid moiety added to the second amino acid of MA, which inserts into the plasma membrane-anchoring Gag ([@bib401]), in addition to a group of positively charged residues within MA ([@bib443]). HIV-1 MA contains a highly basic patch that sequesters the myristate prior to membrane binding and is also capable of binding RNA ([@bib401]). Interestingly, cellular RNAs block binding to nonspecific liposomes but are not able to compete for binding to specific PI(4,5)P2-containing membranes, thus enhancing HIV-1 Gag selectivity for PI(4,5)P~2~-rich membranes ([@bib178], [@bib68], [@bib69], [@bib70], [@bib7]). A cross-linking immunoprecipitation sequencing (CLIP-Seq) study revealed that HIV-1 MA binds almost exclusively to a subset of tRNAs in the cytoplasm ([@bib219]) and recently, specific species of tRNA were shown to block nonspecific Gag membrane binding ([@bib382]). Surprisingly, removal of the nucleocapsid (NC) domain of HIV-1 Gag abolished selective binding, suggesting NC may also play a role in membrane targeting ([@bib382]).

tRNAs may also contribute to the nuclear localization of the preintegration complex (PIC) ([@bib437]). Following reverse transcription, the newly transcribed proviral DNA must be imported into the nucleus for integration of the viral genome into the cellular chromosome ([@bib168]). The CA protein is thought to assist in translocation of the PIC into the nucleus in nondividing cells ([@bib95], [@bib229], [@bib428]). Intriguingly, when HeLa cell cytosolic fractions containing high amounts of tRNA were added back to purified PICs and nuclei, nuclear accumulation of the PICs was observed ([@bib437]). Once imported into the nucleus, tRNAs and CA must dissociate from the HIV-1 proviral DNA to allow integration into the host genome ([@bib95]). Transportin 3 (TNPO3) was found to bind and export tRNAs and CA in a RanGTP-dependent manner, facilitating efficient uncoating of the viral genome after nuclear entry ([@bib442]). TNPO3 is implicated in the nuclear export of defective tRNAs, including those lacking the 3′ CCA end ([@bib437]). The export of defective tRNAs to the cytoplasm is counterproductive to protein translation, suggesting the defective tRNAs may function as tRFs ([@bib442]).

7SL RNA {#s0025}
-------

7SL RNA is packaged at high concentrations by all retroviruses that have been examined to date including MLV, HIV-1, avian retroviruses, feline leukemia virus, visna virus, and equine infectious anemia virus ([@bib378], [@bib32], [@bib44], [@bib58], [@bib97], [@bib234], [@bib245], [@bib306]). Besides genomic RNA and tRNAs, 7SL RNA is the most well-characterized ncRNA packaged into virions. In eukaryotes, 7SL is a 300-nt RNA named according to its sedimentation coefficient and was first identified as a prevalent RNA in RSV particles ([@bib32], [@bib389]). Within the cell, 7SL RNA is part of the signal recognition particle (SRP) ribonucleoprotein complex (RNP), which functions in regulating the secretion of proteins in mammals ([@bib389], [@bib406]). As protein translation occurs, hydrophobic sequences at the N-terminus of nascent peptides are recognized by the SRP ([@bib79]), which is composed of six proteins (SRP9, 14, 19, 54, 68, and 72) and 7SL RNA. Once bound to membrane or secretory proteins, SRP is responsible for targeting these growing proteins to the endoplasmic reticulum (ER) for further distribution ([@bib406], [@bib79], [@bib255]). In addition to acting as scaffolding for the assembly of the SRP proteins, the RNA has roles in accelerating the binding to the SRP receptor on the ER surface and triggering conformational changes that induce GTP hydrolysis by the receptor ([@bib378], [@bib79]).

In the case of retroviruses, 7SL RNA is highly enriched in virions ([@bib32], [@bib106], [@bib405], [@bib42], [@bib407], [@bib198]). For example, in HIV-1 virions, there are 14 copies of 7SL packaged in comparison with 2 copies of gRNA per HIV-1 virion ([@bib297]). Interestingly, although 7SL RNA is predominantly found within the SRP, major SRP components SRP19 and 54 have not been found in virions, while minimal amounts of SPR14 are encapsidated ([@bib99], [@bib408]). These studies suggest that viral 7SL is newly synthesized and diverted to assembling virions prior to assembly of the larger RNP ([@bib99]). Although the exact mechanism of packaging remains unclear, 7SL RNA was shown to be encapsidated into minimal VLPs containing a mini-Gag construct, which contains the first 12 amino acids of matrix followed by the C-terminal domain of CA and a leucine zipper in the place of NC ([@bib199]). A different report suggested NC was required for 7SL RNA packaging ([@bib407], [@bib380]). Many questions remain as to the role of cellular ncRNAs that are packaged into virions. 7SL and other packaged cellular RNA may act as nonspecific nucleating factors for initiation of retroviral Gag multimerization in the cytoplasm ([@bib378]). In a recent study, MS2-stem loops were used to label and track 7SL RNA during HIV-1 infection ([@bib179]). This study revealed that Gag and 7SL RNA arrived at the PM simultaneously, consistent with a model wherein 7SL RNA and lower-order multimers of Gag interact in the cytoplasm prior to assembly at the PM ([@bib179]). Alternatively, 7SL RNA has been proposed to facilitate apolipoprotein B mRNA-editing catalytic polypeptide--like 3G and 3F (APOBEC3G, -3F) packaging ([@bib407], [@bib408]). APOBEC family members are cytidine deaminases that modify RNA, DNA and, in the case of APOBEC3 family members, the HIV-1 genome ([@bib183], [@bib354]). In virions lacking Vif, which induces the degradation of APOBEC3G, hypermutations of the viral genome are found in the form of C- to U- changes ([@bib152], [@bib225]). APOBEC3C, 3F, 3A, and 3B also appear to possess broad antiviral activities against viruses including simian immunodeficiency virus (SIV), MLV, hepatitis B virus, and some endogenous retroelements ([@bib387], [@bib36], [@bib62], [@bib107], [@bib286]). APOBEC3G immunoprecipitated from 293 and Jurkat cells copurified with Y RNAs, specifically Y1, and Y3, and 7SL RNA ([@bib407]). Overexpression of 7SL binding partner SRP19 in 293T cells reduced levels of packaged 7SL RNA and APOBEC3G, whereas overexpression of 7SL RNA increased inclusion of both components into HIV-1 virions ([@bib407]). Similar results were found with APBOPEC3F, suggesting other ABOBEC3 family members may also interact with 7SL ([@bib408]). The authors suggested that the potentially conserved interaction between APOBEC3G and 7SL could explain the more general antiviral nature of the protein and provide a reason for the abundant 7SL RNA present in retroviruses ([@bib407]).

U Small Nuclear RNA {#s0030}
-------------------

U snRNAs are associated with pre-mRNA splicing machinery and are between 60 and 450-nt in length ([@bib208]). All known U snRNAs are transcribed by RNA polymerase II with the exception of U6, which is transcribed by RNA polymerase III ([@bib273]). Although U1, U2, U3, U4, U5, and U6 snRNAs have been found in MLV virions, U6 is the only one detected at levels that approach those of 7SL RNA, whereas the others are much lower in abundance ([@bib296]). Interestingly, in HIV-1 virions, 3′-extended forms of pre-U1 snRNAs were detected at low levels indicating that these RNAs had not been fully processed and are likely packaged as newly transcribed RNAs ([@bib99], [@bib101]). RSV virions were found to contain approximately one U6 snRNA per virion and trace amounts of U1 and U2 ([@bib126]). Interestingly, the authors also found products of reverse transcription that matched U6, U1, and U2 RNA suggesting that RT may use packaged cellular RNA to create recombinant viral genomes ([@bib126]). It is surprising that snRNAs are frequently found in retrovirus virions as they are exclusively found in the nucleus and most retroviruses bud from the cytoplasmic membrane ([@bib126]).

Y RNA {#s0035}
-----

Y RNAs are small ∼100-nt RNAs that are present in the cytoplasm of most vertebrates and some lower eukaryotes in complex with the Ro Protein ([@bib155], [@bib359], [@bib293], [@bib60]). The number of different Y RNAs depends on the species; the human genome encodes four Y RNAs denoted as hY1, hY3, hY4, and hY5 ([@bib292]). Upon transcription of Y RNAs by RNA polymerase III, Y RNA is transiently bound by the La protein and ultimately forms a complex with the Ro protein. The Y RNA--Ro complex has an important role in unfolded and mutated RNA degradation ([@bib424]). Several roles for Y RNA have been proposed: (1) the Y RNA-binding site on Ro overlaps the target RNA-binding site, suggesting that Y RNA regulates RNAs, which are bound by Ro, (2) in *Xenopus* oocytes, Ro has been found to bind mutant 5S rRNA and misfolded U2 snRNA, supporting the role of the Ro complex as a scavenger of unfolded RNA, (3) Y RNA-bound Ro is exclusively localized to the cytoplasm, whereas Y RNA-depleted Ro is localized to the nucleus, suggesting Y RNA also regulates Ro trafficking, (4) Y RNA may regulate the ability of Ro to enhance cell survival following UV radiation. Free Y RNA is found in MLV and HIV-1 virions at lower concentrations than 7SL RNA, bolstering the idea that many cellular RNAs are packaged from a newly synthesized pool prior to interaction with their protein complex partners ([@bib296], [@bib121], [@bib60], [@bib292], [@bib320], [@bib356], [@bib61]). The role of Y RNAs in viral replication is unknown; however, there is an enrichment of mouse Y1 (mY1) and mY3 RNAs even in the absence of Ro, when cellular Y RNAs are degraded, showing there is a selectivity for the virus to package these RNAs ([@bib121]).

Vault RNA {#s0040}
---------

Within the cytoplasm of eukaryotes, large RNP particles consisting of three proteins \[major vault protein (MVP), poly(ADP-ribosyl) polymerase (VPARP), and telomerase/vault-associated protein (TEP1)\] and multiple small ncRNAs are known as vaults. These RNPs are roughly three times larger than ribosomes with a molecular mass of 13 MDa ([@bib196], [@bib203], [@bib364]). vltRNAs are 80- to 150-nt long and vary considerably in sequence but are characterized by a GC-rich stem--loop 5′ to a box A promoter sequence ([@bib364]). The purpose of the vaults is not well understood despite the fact that they are conserved across most eukaryotic species except *Drosophila*, *Arabidopsis*, *Caenorhabditis*, and *Saccharomyces cerevisiae* ([@bib364]). Human vaults are the best characterized and are thought to primarily function in general intracellular transportation and have been implicated as a contributing factor to drug resistance by exporting chemical compounds ([@bib203], [@bib364], [@bib366]). However, other roles have been attributed to vaults and vltRNAs, which are able to fold into structures similar to pri-miRNAs and be processed by Dicer into functional miRNA. Upregulation of vaults correlated with drug resistance to cancer therapeutics in some studies, and vltRNAs are also upregulated during Epstein--Barr virus infection (EBV) ([@bib305], [@bib210], [@bib211], [@bib288]). Of relevance to the retrovirus field is the fact that MVP alone can form vaultlike particles ([@bib367]) reminiscent of VLPs produced by Gag. Additionally, a study of all cellular RNAs packaged into MLV virions identified the presence of previously undetected vltRNAs ([@bib99]). The proteins associated with vaults have not been found in virions to date.

High-Throughput RNA-Sequencing Studies {#s0045}
--------------------------------------

With advancements in the ability to perform whole-cell RNA sequencing, more recent studies have been conducted to examine ncRNA interactions with viral proteins within the cell and to identify RNAs packaged into virions ([@bib100], [@bib101], [@bib296], [@bib219]). CLIP-Seq was used to determine which cellular and vRNAs are preferentially bound by different domains of Gag ([@bib219]). During the initial stages of HIV-1 viral assembly, the NC domain of Gag bound to the genomic RNA packaging signal, psi, and to the Rev response element, as well as to GU-rich mRNA transcripts. However, at the plasma membrane, NC preferentially bound to A-rich regions of both the viral genome and mRNA ([@bib219]). Surprisingly, HIV-1 MA almost exclusively bound host tRNAs in the cytoplasm, as mentioned earlier, and did not interact with the genomic RNA ([@bib219]). However, HIV-1 MA isolated from membrane fractions showed significantly less bound tRNA ([@bib219]), which is in agreement with reports indicating that host tRNAs regulate HIV-1 MA--Gag plasma membrane targeting, as discussed earlier ([@bib69], [@bib70], [@bib382], [@bib93]). A high-throughput RNA-sequencing (RNA-seq) method has also been applied to identify RNAs packaged into HIV-1 virions, revealing several RNAs that had not been detected in previous studies, including many unprocessed RNA species, such as pre-tRNAs, mentioned earlier, and pre-snRNAs ([@bib101]). Future applications of RNA-seq to other retroviruses may uncover RNAs that are universally packaged into virions and those that are selective to specific viruses.

Long Noncoding RNA and Endogenous Retroviruses {#s0050}
==============================================

lncRNAs are not abundantly packaged into retroviral virions with the exception of 7SL RNA and some long interspersed nuclear elements ([@bib414]). Classification of lncRNA is typically more difficult than short ncRNAs, which have well-defined features ([@bib363]). They are generally split into six groups: pseudogenes (mutated gene sequence that no longer code functional genes); long intronic ncRNA; divergent transcripts (associated with and enhance promoters); large intergenic RNA (occurring between coding regions); circular RNA; and natural antisense transcripts ([@bib397]). Although lncRNAs are abundant within the human genome, only a few are well characterized ([@bib124]). Those with known functions include roles in cell cycle regulation, telomerase regulation, chromatin remodeling, and scaffolding for protein complexes. Many have been associated with diseases, including Alzheimer's disease ([@bib276], [@bib118], [@bib124], [@bib137]). Several viruses, including several types of herpesviruses, encode lncRNAs known to interact with and, in some cases, inhibit host proteins, as reviewed in [@bib388]. The human, murine, and avian lncRNAs described below adopt functions that affect retroviral life cycles in diverse ways.

NRON: HIV-1 {#s0055}
-----------

HIV-1 latency and maintenance of virally infected reservoirs has been a central conundrum for the development of effective vaccines and antiviral therapeutic development ([@bib137]). Several host and viral proteins are thought to regulate viral latency including nuclear factor kappa B, nuclear factor of activated T cells (NFAT) and HIV-1 Tat ([@bib192], [@bib287], [@bib207]). Although controversial, host miRNAs are proposed to contribute to viral latency ([@bib208]). Using a large-scale siRNA screen, knockdown of the lncRNA called nonprotein-coding RNA repressor of NFAT (NRON) was found to enhance HIV-1 replication in activated primary CD4^+^ T lymphocytes ([@bib239]). NRON is ∼2700-nt long and its expression was found to be altered over the course of HIV-1 infection; expression is reduced initially due to the viral accessory protein Nef, whereas enhanced expression is observed in the later stages of infection due to Vpu ([@bib175]). NRON was found to affect HIV-1 replication in an NFAT-dependent manner, wherein reduction of NRON resulted in increased activity of NFAT and enhanced viral transcription ([@bib175]). During HIV-1 replication, the viral protein Tat has an essential role in enhancing efficient transcription of the viral genome ([@bib223]). NRON was reported to form a complex with components of the ubiquitin/proteasome, ultimately resulting in the degradation of Tat and reduction of viral transcription in an NFAT-independent mechanism ([@bib239]). NRON is present at high concentrations in resting CD4^+^ T lymphocytes and therefore, may contribute to viral latency via viral transcriptional silencing ([@bib239]).

NEAT1: HIV-1 {#s0060}
------------

Many different types of nuclear and cytoplasmic bodies have been described in cells ([@bib358]). Paraspeckles are dynamic nuclear bodies, the components of which include the 3200-nt lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1). Paraspeckles respond to stress conditions by sequestering components of transcription and halting the production of specific genes; they also sequester a subset of mRNAs to be edited including those containing Alu repeats ([@bib19], [@bib59]). Paraspeckles have also been implicated as an innate immune response to viral infections ([@bib176]). HIV-1 RNA has been reported to be localized to paraspeckles, potentially for A to I editing carried out by ADAR1 ([@bib96], [@bib119]). In one study, the expression profile of over 83 lncRNAs was analyzed during HIV-1 infection of both Jurkat and MT4 cells and NEAT1 expression was found to be increased by 5- to 10-fold ([@bib440]). Knockdown of NEAT1 resulted in reduced paraspeckle formation and increased cytoplasmic concentration of Rev-dependent instability element-containing HIV-1 RNA, enhancing viral replication ([@bib440]).

Large Intergenic RNA--p21: HIV-1 {#s0065}
--------------------------------

During the integration step of the retroviral life cycle, double-strand breaks must be made in the host genome to insert the proviral DNA ([@bib78]). Once inserted, host machinery must repair the break in the phosphodiester bonds before damage to the host DNA triggers cell death ([@bib163]). The proapoptotic protein, p53, is activated when DNA damage occurs, which also activates transcription of lincRNA-p21. The 3100-nt large intergenic RNA (lincRNA)--p21 can induce apoptotic pathways by downregulating the transcription of prosurvival genes ([@bib171]). Expression of lncRNA-p21 is regulated during HIV-1 infection in macrophages to block detection of DNA breaks, allowing HIV-1 to gain control over the MAP2K/ERK2 pathway, one of the targets of lincRNA-p21 that is needed for cell survival ([@bib19]).

Antisense Protein RNA: HIV-1 {#s0070}
----------------------------

In 1988, HIV-1 was proposed to contain an antisense protein (ASP) produced from the antisense promoter within the 3′ LTR based on computational analysis of the viral RNA ([@bib282]). The expression of ASP has been detected in patient sera and induces CD8^+^ T cells ([@bib30]). Possible roles for the ASP RNA include epigenetic silencing of the HIV-1 integrated DNA by recruiting chromatin remodeling proteins to the viral LTR ([@bib438]). This lncRNA is proposed to suppress viral transcription, favoring latency, by enhancing DNA methylation. It is also possible, given the degree of similarity between the 3′ and 5′ LTRs, that ASP RNA acts by forming a triple helix with the 5′ LTR of the genome ([@bib438]). ASP RNA can be detected in chronically infected cell lines and resting CD4^+^ T cells from patients currently taking antiretroviral therapies, demonstrating ASP RNA is expressed in vivo ([@bib438]).

Long Noncoding RNA 00173: HIV-1 {#s0075}
-------------------------------

Analysis of two RNA-seq studies revealed that three lncRNAs were differentially expressed during HIV-1 infection; long noncoding RNA 00173 (LINC00173) was the most evolutionarily conserved prompting further investigation ([@bib312]). Intriguingly, when knocked out, LINC00173 did not impact the retroviral life cycle in Jurkat T cells. However, loss of LINC00173 resulted in higher expression of several cytokines, including interferon-γ, which is important in the adaptive immune response ([@bib312]). Although the authors did not find a direct effect of LINC00173 on HIV-1 infection, they speculate that the increased production of interferon-γ could have implications on an organismal level ([@bib312]).

ASP RNA: HTLV-1 {#s0080}
---------------

The HTLV-1 accessory protein, HTLV-1 basic leucine zipper factor (HBZ) is an ASP whose gene is located near the 3′ viral LTR ([@bib123]). The RNA transcript of this protein has been implicated in cell proliferation leading to HTLV-1-associated diseases and chronic infections ([@bib18]). However, it has also been reported that the mRNA transcript functions by activating antiapoptotic pathways and inducing proliferation by IL-2 independent pathways ([@bib339]). Interestingly, progression to adult T-cell leukemia (ATL) is correlated with increased viral expression ([@bib441]). However, Tax, another accessory protein associated with cell proliferation, is often mutated and inactive in ATL cases, whereas HBZ is expressed, suggesting a role for HBZ protein in chronic infection ([@bib259]). The HBZ mRNA has been shown to be retained within the nucleus indicating a potential functional role in transcription regulation ([@bib321]). The functional HBZ mRNA forms stem--loop structures that function to transcriptionally activate E2F1, a transcription factor upregulated in many cancers, although the mechanism by which this occurs is not understood ([@bib340], [@bib274]). Expression of miRNAs targeting HBZ RNA in ATL cells decreased proliferation of cells ([@bib340]). In mice, HBZ mRNA has been found to activate the transcription of antiapoptotic genes including *survivin*, which may enhance the progression to ATL ([@bib283]).

Bic: ALV and His-1: MLV {#s0085}
-----------------------

ALV infection of birds results in B-cell lymphomas. The virus often integrates at the *bic* locus and is frequently associated with *c*-*myc* activation ([@bib72], [@bib373]). Interestingly, the expression of the proto-oncogenic *c*-*myc* alone is not sufficient to cause lymphoma in avian systems, suggesting that other factors are required ([@bib3]). It was found that insertions at the *bic* locus activated the transcription of a chimeric bic-virus RNA; however, the RNA lacks an open reading frame suggesting it functions as a lncRNA ([@bib373]). In a follow-up study, the expression of bic and c-myc in chicken embryonic fibroblasts induced greater cell growth than activation of *c*-*myc* alone ([@bib374]). However, the coexpression was not sufficient to induce full transformation of cultured cells, suggesting that other genetic changes are required ([@bib374]). While the exact mechanism of the bic lncRNA in cell regulation is still unclear, this discovery was the first report that an lncRNA can interact with and enhance c-myc activity ([@bib374]).

In mice, MLV commonly inserts into the *His*-1 locus, which does not produce any known coding protein ([@bib13]). His-1 transcripts do not contain an open reading frame and the 3000-nt transcript contains multiple stop codons suggesting that it functions through its RNA ([@bib14]). In murine cell lines and mouse tissue, His-1 expression was undetected; however, in two transformed cell lines with detectable MLV insertion near the *His-1* site, increased RNA expression was observed ([@bib14]). Similar to *bic* in ALV, insertion of the MLV genome into the *His-1* locus served to activate the proto-oncogene and enhance cell survival ([@bib14]).

Endogenous Retroviruses {#s0090}
-----------------------

It is estimated that ∼10% of the human genome comprises ERVs, which are considered a type of retrotransposon ([@bib252], [@bib217], [@bib422]). ERVs can arise from the integration of retroviruses in germ cells; inherited viruses are generally unable to replicate due to an accumulation of mutations, frameshifts, and deletions ([@bib125]). Human ERVs (HERVs) are the best characterized, but many animal species also contain ERVs in their genomes including pigs, plants, fish, rodents, insects, and cats ([@bib35], [@bib156], [@bib185]). ERVs are divided into three classes: class I, which resembles gamma- and epsilonretroviruses; class II, which bears similarities to betaretroviruses; and class III, which resembles spumaretroviruses ([@bib252], [@bib125]). Alternative methods of classification use the primer tRNAs to categorize ERVs, see [Table 12.1](#t0010){ref-type="table"} ([@bib125]). Initially, it was thought that ERVs were simply remnants of ancient retroviruses; however, there is increasing evidence that some ERVs have become essential regulatory elements and provide genetic diversity ([@bib412], [@bib253], [@bib230]). Also, although many ERVs do not cause disease, others have been associated with multiple sclerosis, autoimmune disorders, and cancer ([@bib269], [@bib215]). HERV-K is the most intact ERV, with a long open reading frame and ability to produce vRNA and proteins ([@bib252]). HERV-K is also able to illicit a weak immune response, as antibodies to HERV-K proteins are found at very low levels following pregnancies, as well as in patients with leukemias, and certain types of tumors ([@bib252], [@bib341]). The presence of ERVs in pigs, porcine endogenous retrovirus (PERVs), is of special interest as pig tissues can be transplanted into humans. While ERVs are generally innocuous, the consequences of cross-species interactions are unknown ([@bib417]). A recent study examining the transplantation of porcine islet cells into humans for the treatment of type 1 diabetes found no indication of PERV infection up to 113 weeks postimplantation, lending credence to the safety of porcine transplants ([@bib285]). Interestingly, the feline ERV, RD114, was initially detected in a human cell line that had been xenografted into fetal kitten brain tissue, suggesting that xenotropic ERVs are possible ([@bib278], [@bib2], [@bib303]).

Two studies have found that ERVs are important for human stem cell function ([@bib412], [@bib253]). HERV-H silencing in human embryonic stem cells was found to lead to differentiation to fibroblast-like cells ([@bib253]). Using RNA-seq, the levels of HERV-H in human pluripotent stem cells were shown to be elevated compared to embryoid bodies and fibroblasts ([@bib412]). Both studies revealed that HERV-H sites of integration were in regions encoding lncRNAs, prompting the authors to examine the expression of these lncRNAs and adjacent protein-coding regions ([@bib412], [@bib253]). Knockdown of HERV-H also resulted in the reduced expression of neighboring lncRNAs and genes ([@bib253]). It was determined that the HERV-H fragment was acting as a *cis*-gene regulator during stem cell development suggesting that other functional lncRNAs could be derived from ERVs ([@bib253]). Other HERVs have been shown to play roles in cell fusion in the placenta, and fetal tolerance is linked to expression of HERV *env* genes ([@bib33], [@bib270]). Varying levels of HERV expression are observed across many different types of cancer, prompting the examination of HERV activity in tumorigenesis ([@bib334]). Interestingly, HERVs can be inserted into the genome in the antisense orientation, overlapping coding genes. This orientation results in the production of short RNAs complementary to the overlapping gene sequences, creating an inhibitory RNA able to regulate gene expression ([@bib130]). HERV-K, which is generally present in introns, has a functional 3′ LTR expression and was initially inserted into Old World monkey genomes ([@bib46], [@bib84], [@bib261]). *DAP3*, a gene that is located within *HERV*-*K* in HepG2, 293T, and HeLa cells, is a signaling protein that when overexpressed induces apoptosis ([@bib46], [@bib209]). HERV-K antisense RNA fragments were able to reduce levels of DAP3 and, conversely, knockdown of HERV-K transcripts enhanced DAP3 expression to induce apoptosis in HeLa cells ([@bib46]). This finding suggests HERV-K expression could potentially lead to a favorable outcome for tumor formation ([@bib46]). HERV-E was found to be differentially expressed in urotherlial carcinoma cells and coincided with a decrease in cytosolic phospholipase A2, which is often dysregulated in tumor cells ([@bib131]). Although HERV-E transcripts are found in several cancers, including breast cancer, they are also present in normal cell lines implying more studies will need to be conducted before a link between cancers and HERV-E expression is solidified ([@bib131], [@bib115]). Therefore, although ERVs generally do not cause diseases when inserted into host genomes, transcriptionally active portions of the genomes could inherit functional roles within the cell.

Functional Transactivating Response Element RNAs {#s0095}
================================================

Located in the 5′UTR region of the HIV-1 vRNA, the transactivating response (TAR) element forms a stem--loop structure that specifically binds the viral protein Tat ([@bib116]). During transcription, Tat binds to TAR and phosphorylates the C-terminal domain of RNA polymerase II, enhancing transcription of the retroviral genome ([@bib193]). Outside of its essential role in transcription, TAR RNA has also been suggested to have a role in blocking host cellular RNAi responses to HIV-1 infection ([@bib25]). TAR RNA--binding protein (TRBP) is known to interact with Dicer, a component of the RNAi pathway discussed in more detail in [Therapeutics](#s0125){ref-type="sec"} [s]{.ul}ection, by trafficking siRNA to the multiprotein RNA-induced silencing complex (RISC) ([@bib143], [@bib114], [@bib64]). TRBP can be sequestered by TAR RNA, reducing the effectiveness of RNAi within the cell ([@bib25]).

TAR RNA has also been implicated in both *cis*- and *trans*-inhibition of translation within host cells ([@bib302], [@bib102], [@bib353]). TAR RNA can block the ability of the ribosomal initiation factor eIF-4B to effectively recognize the mRNA cap ([@bib302]). Additionally, TAR RNA can be recognized by interferon inducible protein kinase (PKR), which typically recognizes dsRNA, and by 2-5A synthetase, which produces 2′,5′-oligoadenylates that activate RNase L, which can degrade single-stranded vRNA and induce autophagy in response to viral infection ([@bib352], [@bib329]). At low concentrations of TAR, PKR is activated and at high concentrations PKR is inhibited ([@bib262]). Presumably to counteract the ability of PKR and 2-5A synthetase to silence translation, when HIV-1 Tat is expressed, both PKR and 2-5A-synthetase activities are blocked ([@bib262], [@bib190]).

Most cellular mRNA is translated by a cap-dependent mechanism wherein assembling ribosomes scan along the 5′ UTRs to find start codons ([@bib180], [@bib89]). However, the HIV-1 5′ UTR is highly structured and contains stable stem loops including TAR that are capable of hindering ribosomal scanning ([@bib435]). Within the 5′ UTR of several retroviruses, including HIV-1, a posttranscriptional control element (PCE) helps recruit host proteins essential for efficient translation ([@bib37], [@bib38], [@bib172], [@bib335], [@bib326]). Dhx9/RNA helicase A (RHA) is known to interact with PCEs to destabilize structured elements allowing for cap-dependent translation ([@bib153]). RHA interacts with TAR RNA, is packaged into HIV-1 virions, and is important for efficient translation of the HIV-1 vRNA and progeny virion infectivity ([@bib38]). In addition, some cap-dependent cellular translation is downregulated during HIV-1 infection but vRNA is still translated, the possibility of IRESs within the HIV-1 genome has been explored ([@bib4], [@bib43]). Indeed, IRES-like elements within the 5′ UTR and in the *gag* coding frame have been characterized ([@bib89], [@bib43], [@bib47]).

Surprisingly, the TAR element was recently shown to be one of the regions of vRNA to bind to integrase (IN) in HIV-1 virions ([@bib201]). Previously, allosteric IN inhibitors (ALLINIs) had been shown to inhibit late stages of HIV-1, disrupting viral maturation and resulting in impaired viral infectivity ([@bib191], [@bib113], [@bib91]), although the mechanism was unknown. Using CLIP-seq, IN was found to bind discreet regions of the viral RNA including TAR and RRE. Disruption of IN--viral RNA interactions by mutagenesis or treatment with ALLINIs resulted in eccentric viral core formation and reducing infectivity ([@bib201]). The functional significance of this interaction is not completely understood, although it is postulated that the IN--viral RNA interaction may ensure the presence of IN in the CA core and thereby facilitate maturation of the core ([@bib201]).

RNA Interference and miRNAs {#s0100}
===========================

Although plants do not have an immune system in the typical mammalian sense, higher-order plants are able to mount targeted immune responses to viral threats using RNAi ([@bib399], [@bib310]). RNAi was first described in transgenic petunias, wherein introduced genes were silenced through an unknown pathway ([@bib391], [@bib289]). Eventually, it was found that short 21--23 nt siRNAs were targeting mRNAs within the cell, causing the degradation of the RNA and suppression of protein expression ([@bib391]). Over 90% of viruses that infect higher-order plants are transmitted through RNA at some stage of the viral life cycle ([@bib399]). Exogenous viral dsRNA, showing no homology to the host genome, has been shown to trigger the RNAi pathway to suppress vRNA invaders ([@bib104]). It was observed that viruses containing similar gene sequences to those of the plant cell could cause virus-induced gene silencing ([@bib333], [@bib318]). Essentially, viral ssRNA can catalyze the synthesis of dsRNA by plant RNA-dependent RNA polymerases ([@bib310]). The typical RNAi pathway can then occur, ultimately creating siRNAs targeted to the viral genome ([@bib399]). Importantly, this pathway can lead to the production of secondary siRNAs, effectively amplifying the "immune response" ([@bib310]). As for retroviruses discussed below, plant viruses adapt to the host RNAi pathway by producing virally encoded suppressors of RNA silencing ([@bib314]). For example, tomato bushy stunt RNA viruses produce a protein called p19, an inhibitor of Dicer, which blocks the host plant cell's immune response to initial viral infection ([@bib398]).

RNAi, miRNA, and siRNA Production {#s0105}
---------------------------------

The RNAi pathway was initially thought to be unique to plants, but was later identified in many eukaryotic species ([@bib310], [@bib9]). Briefly, RNA Pol II and III recognize specific promoters in DNA to begin transcription of long primary miRNA transcripts (pri-miRNA), usually containing a 33-bp stem loop ([@bib227], [@bib41]) ([Fig 12.1](#f0010){ref-type="fig"} ). Pri-miRNAs produced from RNA Pol II are sensitive to alpha-amanitin, allowing for the identification of the polymerase responsible for transcription ([@bib227]). These transcripts are polyadenylated and capped via a similar mechanism to that used for mRNAs, and like mRNAs, can be edited ([@bib49], [@bib254]). The nuclear microprocessor complex composed of Drosha, an RNase III enzyme, and DGCR8, which contains two dsRNA-binding motifs, cleaves the pri-miRNA 11 bp from the base of the stem--loop structure and the product of this step is pre-miRNA ([@bib226], [@bib147]). Although most miRNAs are processed through Drosha and DGCR8, some miRNAs are formed after intron splicing and can bypass this step ([@bib330]). At this stage, the pre-miRNA is exported to the cytoplasm and further processed by the RISC-loading complex, which consists of the RNase Dicer, TRBP, the protein activator of PKR (PACT) and Ago2, the main component of Argonaute-2 ([@bib134], [@bib228]). TRBP and PACT help to stabilize the pre-miRNA--protein complex, whereas Ago2 creates a nick in the 3′ arm of the stem loop ([@bib228], [@bib94]). Dicer cleaves the remaining loop resulting in a 21--23 nt RNA with 2-nt overhangs on both the 3′ ends ([@bib29]). Although both strands could be utilized as the guide RNA for silencing, it is typical that the one with the least stable 5′ end becomes the functional miRNA, whereas the other one is degraded ([@bib348], [@bib202]). Generally, miRNAs target the 3′ UTRs of mRNA blocking protein translation ([@bib300]). A majority of the mRNAs that are completely complementary to the seed sequence, the minimal portion of miRNA required to recognize the target RNA, will be translationally suppressed, whereas targeted mRNAs with partial complementarity to guide RNAs tend to be degraded ([@bib431], [@bib271], [@bib235]). Many of the steps of this process can be bypassed or altered depending on cellular conditions; for a more detailed review see [@bib423]). Processing bodies (P-bodies) within the cytoplasm of cells appear to be concentrated areas of translationally silenced RNAs, mRNA degradation, and nonsense-mediated decay ([@bib247], [@bib351]). Since the first identification of miRNAs, over 5500 human and 130 viral miRNAs have been predicted ([@bib135], [@bib136], [@bib250], [@bib385]). Expression of miRNAs is tightly regulated within cells and is often tissue specific, leading to the use of miRNAs in diagnostics for various types of cancers, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases ([@bib9]).Figure 12.1MicroRNA (miRNA) production pathway and viral interaction with RNA interference (RNAi) machinery. Host pri-miRNAs are transcribed by RNA polymerase II (Pol II) or III (Pol III) and can be processed by Drosha and DGCR8 into pre-miRNAs. Pre-miRNAs are then exported from the nucleus by exportin-5 and cleaved into a 21--22 nt miRNA duplex by Dicer of the RNA-induced silencing complex (RISC) complex. One miRNA strand is loaded onto the Argonaut (AGO)-RISC complex and used to select mRNAs for degradation or translational silencing. This process is depicted by *black arrows*. Viral miRNA entry into the RNAi pathway is shown in *purple text*. Inhibition of the host RNAi pathway by viral proteins or RNA is indicated by *red text* and *arrows* directed towards their proposed inhibitory target. *ALV*, avian leukosis virus; *BFV*, bovine foamy virus; *BLV*, bovine leukemia virus; *RSV*, Rous sarcoma virus; *SFV*, simian foamy virus; *TRBP*, TAR RNA--binding protein.Adapted from Winter, J., Jung, S., Keller, S., Gregory, R.I., Diederichs, S.S., 2009. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228--234; Trobaugh, D.W., Klimstra, W.B., 2017. MicroRNA regulation of RNA virus replication and pathogenesis. Trends Mol. Med. 23, 80--93; Klase, Z.A., Sampey, G.C., Kashanchi, F., 2013. Retrovirus infected cells contain viral microRNAs. Retrovirology 10, 15; Soifer, H.S., Rossi, J.J., Saetrom, P., 2007. MicroRNAs in disease and potential therapeutic applications. Mol. Ther. 15, 2070--2079.

Effective viral infection requires regulation of various cellular processes including mRNA translation ([@bib19]). HIV-1 infection has been found to modulate the expression of over 300 genes including miRNAs ([@bib19], [@bib300], [@bib396]). The ability of host miRNAs to impact viral replication in mammals has been well characterized. The question remains whether these miRNAs are physiologically capable of directly regulating retroviral replication ([@bib133]). Additionally, many different types of viruses have been found to produce miRNAs from their genomes ([@bib388], [@bib300], [@bib213], [@bib390]). The most widely characterized viral miRNAs are produced from DNA viruses including *Herpesviridae* and mouse cytomegalovirus ([@bib300]). The discovery of viral miRNAs in RNA viruses, such as EBV, was surprising and remains controversial ([@bib388], [@bib213], [@bib164], [@bib82]). First, many RNA viruses replicate exclusively in the cytoplasm, thereby avoiding nuclear Drosha cleavage. In addition, if nuclear RNA genomes were processed into miRNAs very little full-length gRNA would be available to be packaged ([@bib390], [@bib82]). However, some retroviruses have adapted to produce miRNAs by the less frequently used RNA Pol III, addressing the issue of genomic RNA degradation of Pol II transcripts ([@bib213]). Conversely, Drosha and the RNAi pathway can act to inhibit viral replication resulting in potentially beneficial or detrimental outcomes ([@bib19], [@bib390]). Cellular miRNAs are proposed to regulate viral replication ([@bib164], [@bib432]). To counteract cellular antiviral RNAi responses, retroviruses have adapted by degrading RNAi machinery, diversifying the roles attributed to viral proteins, and producing "decoy" RNA transcripts ([@bib25], [@bib164], [@bib432]).

Cellular MicroRNAs Made in Response to Viral Infections {#s0110}
-------------------------------------------------------

Mammalian miRNAs are estimated to regulate up to 30% of protein-coding mRNA and the expression patterns of some miRNAs are modulated upon viral infection ([@bib385], [@bib164]). Host miRNAs can impact viral life cycles both directly and indirectly, leading to either enhanced viral production or suppression of the viral life cycle ([@bib385], [@bib415]). The specificity of the host miRNA response to specific viral infection and whether the RNAi pathway is used as a general antiviral response are active areas of investigation. miRNA pathways identified in specific retroviruses are described below.

*Avian leukosis virus subgroup J (ALV*-*J).* ALV can be transmitted vertically and chicken eggs are used in the development of human vaccines ([@bib120], [@bib173]). Thus, understanding the mechanism of this oncogenic virus' life cycle has been a major undertaking and seems linked to host miRNAs ([@bib83], [@bib237], [@bib238], [@bib410]). Microarray analysis of chicken (*Gallus gallus*) tumors showed differential expression of several miRNAs known to interact with MAPK and Wnt signaling pathways, both associated with tumorigenesis in exogenous ALV-J infections ([@bib410]). These miRNAs include gga-miR-125b, gga-miR-193a, gga-miR-193b, and gga-miR-221. gga-miR-1650 was found to bind the 5′ UTR of the ALV-J gRNA resulting in decreased viral replication ([@bib411]). However, both WT and gga-miR-1650-resistant viruses were able to replicate under endogenous gga-miR-1650 expression indicating a higher level of miRNA expression would be needed to suppress the virus ([@bib411]). Another miRNA found to be upregulated during ALV-J infection was gga-miR-34b-5p, which enhances viral replication by downregulating interferon regulatory factor-1, preventing host responses to viral infections and promoting tumorigenesis ([@bib238]). Another viral sensing target of gga-miR-34b-5p is melanoma differentiation--associated gene 5 (MDA5). MDA5 also controls proliferation, cell cycle progression and migration of ALV-J infected cells, suggesting that gga-miR-34b-5p regulation of host immune responses has a substantial impact on viral replication and disease progression ([@bib240]). Like miRNAs, piwi-interacting RNAs (piRNAs) are also able to silence ALV expression ([@bib369]). These RNAs interact with a subclass of Argonaute proteins, known as PIWI proteins, which result in the cleavage of the targeted RNA ([@bib369]). However, the resulting cleavage products can then be used as secondary piRNAs amplifying the effect ([@bib369]). Using RNA-seq, 73 active transposable elements were identified in White Leghorn testis that elicited piRNA-mediated suppression, suggesting piRNAs have evolved to maintain the integrity of germline genomes ([@bib369]).

*Prototype foamy virus type 1 (PFV-1).* Expression of a silencing suppressor, p19, was found to enhance PFV-1 viral expression in 293T cells leading the authors to speculate that the RNAi pathway was involved in viral regulation ([@bib385], [@bib224]). This study further showed that human miR-32 shared homology with the 3′UTR of all PFV-1 mRNAs and repressed viral expression in a manner that depended on a complementary sequence ([@bib224]). The countermechanism utilized by PVF-1 will be discussed below.

*HTLV-1.* Human miR-28-3p targets the gRNA of HTLV-1 within the *gag/pol* gene causing a halt in translation of the virus in resting T cells ([@bib385], [@bib15]). Interestingly, subtype 1a, the Japanese AKT-1 strain of HTLV-1, contains a single-point mutation within the target sequence creating resistance to miR-28-3p and allows the virus to transmit efficiently ([@bib385], [@bib15]). Computational studies predicting host miRNAs that could target HTLV-1 gRNA revealed several potential candidates, including plus-strand miR-653, -648, -596, -644, -496, -431, -326, -125b, -432, -125a, -663, -939, -1538, and -1908 ([@bib164], [@bib331], [@bib145]). Two miRNAs, miRNA-130b and miRNA-93, have been shown to be upregulated in HTLV-1 infected transformed cells, leading to the speculation that miRNAs may play a role in development of ATL as the normally functioning miRNAs regulate tumor suppressor protein TP53INP1 ([@bib164], [@bib433]).

*HIV-1.* It has been proposed that miRNAs could regulate several steps of the HIV-1 life cycle, either directly by targeting the genomic RNA or indirectly by controlling the cellular environment ([@bib19], [@bib385]). Expression of 62 miRNAs was reported to be altered between uninfected and HIV-1-infected individuals ([@bib165]). Interestingly, knockdown of Drosha and Dicer increased HIV-1 expression, suggesting that the RNAi pathway may regulate HIV-1 infection ([@bib164], [@bib383]). Host miRNAs that have been proposed to target the RNA genome include miR-29a, which is complementary to a region in the *nef* gene ([@bib290], [@bib5]). In addition to simply blocking translation, miR-29a is implicated in the sequestration of HIV-1 RNA in P-bodies and association of the vRNA with RISC components, perhaps functioning in the regulation of viral latency ([@bib290], [@bib55]). Multiple in silico studies have been carried out to predict additional host miRNAs that could target the HIV-1 genome directly, and the list of hits includes miR-149 (*vpr*), -378 (*env*), and -324-5p (*vif*) ([@bib151]). Many studies were performed in specific cell lines or conditions leading to confusion over reproducibility and physiological relevance of miRNAs found to inhibit viral replication; however, the miRNAs uncovered computationally and in some cases experimentally include miR-133b, -138, -149, -326, -92a, -28b, -125b, -150, -223, -382, -29b-3p, -33a-5p, 423, -301a, and -155 ([@bib19], [@bib385], [@bib164], [@bib5], [@bib166], [@bib170], [@bib322], [@bib419]). A cluster of miRNAs, miR-28, miR-125b, miR150, miR-223, and miR-382, are proposed to bind to the 3′UTR of the HIV-1 RNA, suppressing expression of viral proteins and ultimately contributing to viral latency in resting CD4^+^ T cells ([@bib170]). Certain cells are less susceptible to HIV-1 infection, including peripheral blood monocytes, whereas tissue macrophages are efficiently infected ([@bib197], [@bib299]). As miRNA expression is generally tissue specific, the levels of putative anti-HIV-1 miRNAs (miR28, -150, 223, and 382) were examined in monocytes and macrophages ([@bib409]). Interestingly, monocytes were found to have higher expression levels of these miRNAs than those differentiated into macrophages. Moreover, monocytes in which the targeted miRNAs were knocked down were more permissive to infection, suggesting that the differences in miRNA expression may contribute to viral permissiveness ([@bib409]). Several cellular miRNAs indirectly impacting the HIV-1 life cycle have also been described including miR-20a, -17-5p, -1236, -15a/b, -16, -93, -106b, -198, -27b, -29b, -223, -150, -155, -146a, -888, -132, and -217 ([@bib19], [@bib383], [@bib258], [@bib355], [@bib370], [@bib57], [@bib371], [@bib63], [@bib66], [@bib439]). These miRNAs are proposed to have a wide array of functions including suppressing HIV-1 infection by restricting nuclear import of the PIC, cell cycle regulation, and enhancing transcriptional activation of latent viral genomes ([@bib19], [@bib258], [@bib371], [@bib66]). During the progression of HIV-1 infection, many patients develop HIV-associated neurocognitive disorders (HAND) ([@bib427]). Numerous miRNAs were found to have abnormal expression in brain tissue of patients with HAND, including miR-500a-5p, miR-93-3p, miR34c-3p, and miR-381-3p, which were found to be upregulated ([@bib427]). These miRNAs target peroxisome biogenesis factors, resulting in depletion of peroxisomes during HIV-1 infection, which typically plays a role in lipid metabolism and antiviral signaling ([@bib427]). Reduction in peroxisomes over time may contribute to neurological disorders in HIV-1 patients ([@bib427]).

Viral MicroRNAs Encoded Within Genomes {#s0115}
--------------------------------------

The existence of miRNAs produced from a viral genome was first described for EBV genomic RNA, wherein five miRNAs were initially discovered in 2004 ([@bib307]). Since this early report, computational predictions and experimental evidence support the existence of miRNAs produced from viral genomes, including retroviruses ([@bib388], [@bib137], [@bib300], [@bib213], [@bib164]). However, many of these miRNAs appear to be expressed at very low levels within the cell and specific functions have yet to be identified for the majority. Coupled with difficulties in reproducibility, the relevance of these transcripts remains a topic of debate ([@bib26], [@bib300], [@bib164], [@bib244]). A general set of guidelines for the identification of viral miRNAs has been suggested ([@bib388], [@bib213]) including: (1) any ncRNA produced must have importance in the viral life cycle due to space limitations of the genome; (2) the levels of miRNA should be detectable by deep sequencing, indicating that they are expressed at functional concentrations; and (3) the miRNA must have a defined role and should be conserved across clades. Specific examples of miRNAs in retroviral genomes are described below.

*Bovine leukemia virus (BLV)*. One of the early questions regarding miRNA production from retroviruses revolved around how the genome could avoid being processed by the RNAi machinery ([@bib82]). Pol II transcripts are the main substrate for the RNAi pathway; however, as mentioned above, Pol III transcripts are occasionally used ([@bib227], [@bib41]). Pre-miRNAs transcribed by Pol III are able to bypass Drosha processing, protecting the vRNA from cleavage ([@bib82], [@bib205]). As an example, BLV was found to encode a cluster of five miRNAs within SL1 and SL2 stem loops in the 5′UTR named BLV-miR-B1-5 ([@bib205]). Interestingly, BLV-miR-B4 has an identical seed sequence to host miR-29, which has previously been implicated in transformation of B cells in mice, and is sufficient to induce tumor formation ([@bib205], [@bib148], [@bib337]). The natural hosts of BLV are cattle, which develop atypical B-cell (CD5^+^) tumors that are BLV+ but produce very little viral mRNA, leading to the hypothesis that BLV-miR-B4 may contribute to tumorigenesis ([@bib127], [@bib233]). BLV-miR-B2-5p also shares sequence identity with a host miRNA, miR-943, which has been tied to tumor suppressor p53, hinting at roles for the other BLV-miRs in tumor formation ([@bib205], [@bib56]). In another study, BLV miRNAs were found to be present in leukemic B cells isolated from sheep infected with BLV without detectable levels of Pol II driven viral LTR transcription, supporting the conclusion that miRNAs contribute to a tumorigenic state even in the absence of detectable viral production ([@bib327]). The viral miRNAs constituted a high percentage of the host miRNA pool (∼40%) and were present in amounts up to 80,000 copies per cell ([@bib327]). While the BLV miRNAs may contribute significantly to tumorigenesis, it is also possible that they could lead to viral latency, as suggested for miRNAs produced from other retroviral genomes ([@bib327], [@bib212]). A recent report examined the transcriptomic profile of cells transduced with the BLV miRNAs to identify potential direct and indirect targets and to delineate their impact on the BLV life cycle and B-cell transformation ([@bib128]). Several mRNAs were found to be targeted by BLV miRNAs, including GZMA, FOS, PPT1, ANXA1, MAP2K1 and PIK3CG, whose gene products are involved in apoptosis, immunity, cell signaling, and oncogenesis pathways ([@bib128], [@bib144], [@bib243], [@bib138]). Deletion of miRNAs from the BLV genome leads to decreased viral loads, arguing for a potential role in the viral life cycle; however, the specific role of miRNA is still unknown ([@bib128]). Intriguingly, BLV is also associated with breast cancer and it has been suggested that a new BLV vaccine in development may exclude attenuated viruses containing miRNAs due to their potential role in tumorigenesis ([@bib128], [@bib48], [@bib142]).

*Bovine foamy Virus (BFV)*. Three BFV miRNAs produced from the viral genome have been described ([@bib420]). BFV miRNAs are transcribed by RNA Pol III as a single transcript from the *bet* gene ([@bib388], [@bib420]). However, unlike BLV where the pre-miRNA is exported into the cytoplasm bypassing Drosha, it appears that initial processing of the pri-miRNA transcript may be carried out by Drosha ([@bib420]). BFV miR-BF2-5p and miR-BF1-5p are highly expressed in chronically infected cells, accounting for over 50% and 19% of all small RNA within the cell, respectively ([@bib420]). These miRNAs are also detected in calves 6 months postinfection, indicating that they are expressed in vivo, although the impact of miRNA expression remains unknown ([@bib420]). The seed sequence of miR-BF1-5p is identical to miR-B5, a miRNA expressed from the bovine herpesvirus 1, suggesting they may have a common target ([@bib420], [@bib129]).

*ALV and RSV*. A *cis*-acting element within ALV-J genomes, E (XSR), encodes a 148-nt ncRNA that has the ability to fold into a stem--loop structure similar to those processed by Dicer ([@bib429], [@bib65]). The XSR element is conserved across most ALV-J isolates and appears to contribute to oncogenesis in some cases ([@bib65], [@bib426]). Deep sequencing of an ALV cell line revealed the XSR element produced a miRNA ([@bib429]). Unlike the other retrovirus miRNAs described above, alpha-amanitin blocked expression of the viral miRNA, indicating that transcription is Pol II dependent ([@bib429]). This was the first description of a retrovirus using the canonical RNAi pathway to produce viral miRNAs.

*Simian foamy Virus (SFV)*. Putative viral miRNAs were also predicted to be produced from the SFV genome using a combined computational and synthetic approach ([@bib213], [@bib206]). Two miRNAs, SFVagm-miR-S4 and SFVagm-miR-S6, were shown to be produced in cells transfected with the proviral African green monkey SFV genome and corresponded to sequences in the LTR ([@bib388], [@bib206]). While the miRNAs are transcribed by RNA Pol III, knockdown of Drosha resulted in decreased viral miRNA production, indicating Drosha processing is necessary for expression ([@bib206]). Like other viral miRNAs, SFVagm-miR-S4 and SFVagm-miR-S6 share seed sequences with host miRNAs, miR-155, and miR-132/212, respectively ([@bib206]). Host miR-155 is associated with cell survival and proliferation, and mimics of this miRNA have been found encoded in several herpesvirus genomes ([@bib206], [@bib132], [@bib246], [@bib357]). Similarly, the miRNA family 132/212 is implicated in innate immunity, and the miRNAs are upregulated during Kaposi's sarcoma--associated herpesvirus infection ([@bib206], [@bib220]). Although the SFV miRNAs resemble host miRNAs that play roles in herpesvirus infection, the relevance of their expression to the SFV life cycle is unknown.

*HIV-1*. Although several miRNAs are predicted to originate from the HIV-1 genome, the topic remains controversial due to difficulties in reproducibility ([@bib137], [@bib213], [@bib390], [@bib244], [@bib308]). Although many retroviral miRNAs appear to mimic host miRNAs that modulate the cellular environment, HIV-1 viral miRNAs appear to target the virus itself to regulate latency ([@bib137], [@bib300], [@bib213], [@bib164]). In silico methods initially predicted that HIV-1 encoded five miRNAs within the TAR stem loop, R region, *gag*, *gag*-*pol* frame shift, and *nef* ([@bib164], [@bib23]). Subsequently, a study was published illustrating the ability of miR-N367, produced from the *nef* region of the viral genome, to negatively regulate HIV-1 expression, potentially contributing to viral latency ([@bib295]). The 5′UTR of HIV-1 is highly structured and contains many features critical to the viral life cycle including the Psi packaging signal ([@bib17]) and TAR; the latter forms a stable stem--loop integral to efficient transcription through binding to the Tat protein ([@bib122]). In the absence of Tat, for instance, potentially during latency, only short viral transcripts are made that contain TAR RNA ([@bib110], [@bib392]). In addition to sequestering TRBP, TAR RNA is capable of being processed by dicer and miRNAs derived from this region were detected by RNase-protection assays in infected T cells ([@bib212]). One TAR-derived miRNA was found to recruit HDAC-1, a histone deacetylase associated with HIV-1 latency, to the viral LTR ([@bib212]). TAR RNA-derived miRNAs, miR-TAR-5p and -3p, have also been identified at low levels ([@bib301]). Another conserved double-stranded region of the HIV-1 RNA genome is formed when tRNA^Lys3^ is annealed to the PBS ([@bib168]). This region was found to associate with Ago2 of the RISC complex, potentially activating the RNAi pathway as an antiviral response to infection ([@bib434]). Intriguingly, the PBS:tRNA hybrid region appears to be processed into miRNAs in ERVs from mice and humans, implicating the host RNAi machinery in viral suppression ([@bib50], [@bib194]). Although, the HIV-1 gRNA--tRNA hybrid-derived ncRNA was also found in a later deep sequencing study, the authors concluded it was more likely a degradation product of tRNA^Lys3^ due to its presence in uninfected controls ([@bib346]). Another in silico alignment of matching regions of the HIV-1 genome and host mRNAs involved in immune responses predicted multiple targets for viral miRNA, though they remain to be validated ([@bib137], [@bib77]). An *env* derived miRNA was found to inhibit HIV-1 expression similar to TAR-derived miRNA; however, in the presence of Tat, this inhibitory effect was largely abolished suggesting the virus had found a way to adapt to the host RNAi response ([@bib24]).

Viral Suppressors of RNA Silencing {#s0120}
----------------------------------

Retroviruses are notorious for their ability to evade host defenses, whether directly through accessory proteins or by modulating translation to favor viral protein production ([@bib266]). Many plant viruses and some insect viruses have adapted to RNAi immune responses by evolving suppressors of RNA silencing (SRS) with the ability to bind and block the function of RISC components or to sequester miRNAs directed against the virus ([@bib398], [@bib390], [@bib236]). As mentioned above, tomato bushy stunt virus encodes a protein, p19, which functions by binding specifically to short dsRNAs containing the typical 2-nt overhang associated with miRNAs, effectively blocking RISC:miRNA association ([@bib390], [@bib315], [@bib344]). Therefore, it was natural, given the involvement of RNAi in other viral life cycles, to suspect that retroviral genomes might also contain SRS proteins or broaden the functions of existing viral proteins to serve this role ([@bib164]). Tat has also been implicated as an SRS protein, possibly through hindering Dicer activity ([@bib24], [@bib22]). HTLV-1 encodes an accessory protein, Rex, which binds to the Rex-response element and facilitates export of incompletely spliced viral mRNAs ([@bib16], [@bib218], [@bib436]). As a potential SRS, Rex is able to block the processing of pri-miRNA by Dicer, although whether the suppression is mediated through dsRNA sequestration or direct binding to Dicer is unknown ([@bib1]). The traditional role of the PFV Tas protein is as a transactivator of PFV transcription ([@bib108]). As mentioned above, host miR-32 targets PFV to inhibit translation of viral proteins ([@bib224]). However, Tas expression caused an accumulation of host miRNA and ameliorated translational repression, supporting Tas as a general RNAi suppressor ([@bib224]). Several studies have also been published showing little effect of Tas, Rex, and Tat proteins on the host RNA silencing pathway and argue that the interferon system is much more sensitive and effective than the SRS pathway in mammals ([@bib390], [@bib244]).

Therapeutics {#s0125}
============

Current retroviral treatments for HIV-1 require daily doses of highly active antiretroviral therapy, a combinational regimen targeting multiple steps of the retroviral life cycle ([@bib140]). Unfortunately, over time the virus is able to adapt, requiring the patient to switch antivirals to avoid viral rebound ([@bib71], [@bib375]). Additionally, the side effects caused by treatment are often severe and worsen over time, resulting in nonadherence to the therapy schedule, which can result in selective pressure for viral mutagenesis under suboptimal concentrations of inhibitors ([@bib85]). With the discovery of RNAi, a potential new approach to viral treatment became available, wherein viral translation could be targeted and suppressed by introduction of engineered small-hairpin RNAs (shRNAs) ([@bib182]). Applying siRNA strategies to other viral and cancer targets has been employed with varying degrees of success ([@bib385], [@bib20], [@bib394], [@bib221], [@bib98], [@bib361]). Several problems have plagued the development of siRNA-based therapeutics, including efficient delivery to targeted tissues, viral escape through mutagenesis, saturation of RNAi machinery, and stability of introduced siRNAs ([@bib9], [@bib385], [@bib164], [@bib394], [@bib216], [@bib174]). An shRNA vaccine for poliovirus has been tested and found comparable to the Sabin type 1 poliovirus vaccine in mice, although partial deletions of the target viral sequence occur ([@bib20]). Hepatitis C virus (HCV), a causative agent of liver disease, was the target of another study, as miR-122 is necessary for HCV infection ([@bib188], [@bib189]). Weekly injections of a locked nucleic acid--modified oligonucleotide complementary to miR-122 reduced levels of HCV RNA in infected chimpanzees without viral mutation or deleterious side effects ([@bib221]). Additionally, a more recent study attempted to create a siRNA therapeutic against Ebola virus disease. Unfortunately, the siRNA-loaded lipid nanoparticles did not significantly increase survival rates ([@bib98]).

Single siRNA species were initially used to target specific regions in the HIV-1 genome ([@bib87], [@bib34], [@bib232], [@bib418]). For example, a single shRNA directed against *tat* was able to repress HIV-1 transcription by 95% ([@bib34]). However, when cultured for longer periods of time, HIV-1 was able to adapt by a single-point mutation rendering the shRNA ineffective ([@bib34]). Continuous inhibition of HIV-1 using an siRNA against *nef* was found to induce viral mutation and eventual escape ([@bib87]). Interestingly, while viral escape has been linked to point mutations conferring resistance to siRNAs, a follow-up study found that some HIV-1 viral escape mutants resulted in mutations outside of the target sequence resulting in structural changes in the viral RNA ([@bib418]). In another example of unusual viral escape, siRNAs against the TAR stem loop resulted in compensatory mutations in the promoter region that enhanced viral transcription ([@bib232]). As with antiretroviral drugs, siRNA therapy would most likely need to be given in combination for successful inhibition ([@bib87], [@bib34]). In silico predictions suggested that expression of at least four shRNAs would be needed to maintain a high degree of viral repression and decrease the ability of HIV-1 to evade silencing ([@bib12]). This was corroborated with lentiviral transduction of a combination of four siRNAs targeting Gag, Pol, and R/T-5 regions of HIV-1. Using this approach, HIV-1 replication was inhibited for 40 days without viral escape, although some viral spread was observed, suggesting the RNAi pathway could have been saturated ([@bib379]). It also became clear that to sustain expression of siRNAs, lentiviral vectors lacking any sequence repetition would be necessary to avoid recombination and to induce stably expressing cells ([@bib12], [@bib379]). Intriguingly, HIV-1 mutations tend to follow predictable routes, leading to the concept of coupling second generation siRNA species targeting likely resistance mutations to primary siRNA treatments, thereby enhancing the effectiveness of siRNAs ([@bib345]). Unfortunately, even with the use of second-generation siRNAs, the virus was still able to escape restriction, adapting with novel mutations ([@bib345]). An additional concern of shRNA therapy is the reduced expression of Dicer in monocytes ([@bib73]). However, a subset of shorter shRNAs are able to bypass dicer, instead being processed by Ago2 directly and creating a single guide strand, AgoshRNAs ([@bib248]). This approach presents several advantages to traditional shRNAs, including limited off-target toxicity from the passenger strand ([@bib159], [@bib158]). Successful AgoshRNAs have been designed against the CCR5 coreceptor, Gag, and Pol ([@bib159], [@bib158]).

Another approach to RNA-based therapeutics is to cleave or delete portions of the integrated or RNA HIV-1 genome through targeted enzymatic activities to disrupt the life cycle ([@bib284], [@bib157], [@bib10], [@bib328]). Transducing CD34^+^ hematopoietic stem cells with a ribozyme targeted to the *vpr/tat* reading frames and introducing them into HIV+ patients resulted in a slightly decreased viral load ([@bib284]). Although the transduced stem cell percentage was likely low, there were no reported negative effects, providing evidence that gene therapy is possible ([@bib284]). Zinc-finger nucleases, recombinases and transcription activator--like effector nuclease strategies have been developed for HIV-1 treatment and several have been examined in clinical trials ([@bib338], [@bib377], [@bib316]). With the development of the clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated (Cas) editing system, new approaches to gene therapy have become available ([@bib157]). This system relies on guide RNAs that target specific sequences of DNA, which in turn can be cleaved by the endonuclease, Cas9 ([@bib167]). Although this technique has several advantages, it does require the introduction of the relatively large CRISPR and Cas9 into the genome, which is accomplished by production of stable target cell lines expressing humanized Cas9 and several guide RNA sequences by lentiviral transduction ([@bib413]). However, HIV-1 has been shown to alter nucleotides around the cleavage site to reduce effectiveness of Cas9 ([@bib167]). Additionally, introduction of CRISPR/Cas can actually accelerate viral escape because once the viral DNA is cleaved, nonhomologous end joining machinery can repair the dsDNA breaks creating resistant viruses within 36 h of infection ([@bib413], [@bib241]). Alternative nonviral targets have been suggested to limit the spread of HIV-1 infection, including the coreceptors CXCR4 and CCR5. Mutation of CXCR4 and CCR5 has been successful in conferring resistance against viral infection, which could be used in combination therapies ([@bib162], [@bib430]). Although there are still many aspects of gene therapy that need to be studied and understood in more detail, great strides have been made in the area of RNA-based therapeutics. Many of the lessons learned have been applied to general techniques in the field of virology and cell biology, including the development of stable lentiviral gene--silencing approaches ([@bib167], [@bib368]).

Concluding Remarks {#s0130}
==================

The discovery that the human genome is predominantly composed of ncRNA has propelled the field of RNA biology into many new areas, such as exogenous siRNA gene regulation, and has led to a deeper understanding of cellular biology. It is now clear that ncRNAs are critical to cellular responses ranging from general homeostasis to the disease states of viral infection and cancer. RNAs that were once considered to be well understood, such as tRNAs, are now thought to possess many alternative functions, including those mediated by tRNA fragments. Many newly discovered ncRNAs, such as vltRNAs, are still being characterized at a basic level. The impact of RNA on retroviral life cycles will undoubtedly grow as novel roles for cellular and viral ncRNA continue to be elucidated. Breakthroughs that have been made in the field to date lay the groundwork for future endeavors that could lead to the development of effective RNA-based therapies.
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[^1]: *ALV*, avian leukosis virus; *BFV*, bovine foamy virus; *BLV*, bovine leukemia virus; *EFV*, equine foamy virus; *EIAV*, equine infectious anemia virus; *FFV*, feline foamy virus; *FIV*, feline immunodeficiency virus; *FLV*, feline leukemia virus; *GALV*, gibbon ape leukemia virus; *HERV*, human endogenous retrovirus; *HTLV*, human T-cell leukemia lymphoma virus; *KoRV*, Koala retrovirus; *MLV*, murine leukemia virus; *RSV*, Rous sarcoma virus; *SIV*, simian immunodeficiency virus; *SFV*, simian foamy virus; *PFV*, prototype foamy virus.

[^2]: Mammalian tRNA^Lys^ has two isoacceptors, CUU and UUU. The human genome encodes at least 44 putative tRNA^Lys^ species ([@bib251]-<http://gtrnadb.ucsc.edu>) that have slight variation outside of the anticodon, i.e., isodecoders. Therefore, tRNA^Lys1,2^ represents tRNA^Lys,CUU^ with 24 different isodecoders and tRNA^Lys3^ represents tRNA^Lys,UUU^ with 20 different isodecoders. Whether all of these are expressed and function as tRNAs in translation or as primers is unknown.

[^3]: tRNA primer varies depending on specific HERV species, however, many use tRNA^Lys^ isoacceptors.
